| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8651064 | American Heart Journal | 2018 | 26 Pages |
Abstract
TA when left to physicians' discretion was used in high-risk patients, was associated with bailout use of glycoprotein IIb/IIIa inhibitors and TIMI major bleeding, and had no impact on 30-day clinical outcomes. Conversely, pre-H ticagrelor treatment predicted lower 30-day rates of ST or new MI without interaction with TA.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sinem MD, Enrico MD, Arnoud W.J MD, PhD, Christian W. MD, Frédéric MD, PhD, Jens Flensted MD, PhD, Anne MD, Abdourahmane MD, Eric MD, PhD, Gilles MD, PhD, for the ATLANTIC Investigators for the ATLANTIC Investigators,